Evidence map›Paper›PMID 42836196›Full record

ArticleResearch in pharmaceutical sciences2026

Thiolactomycin-based morpholino and piperidino conjugates: synthesis, antimalarial evaluation, and P

Shaik Azeeza, M Shaheer Malik, Qazi Mohammad Sajid Jamal, Mufakham Ali Mohammad, Munirah M Al-Rooqi, Saeed S Samman, Shaikh Thoukhir Basha, Abdulrahman A Alsimaree, Ziad Moussa, Saleh A Ahmed and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Research in pharmaceutical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Shaik AzeezaDepartment of Medicinal Chemistry and Pharmacology, CSIR- Indian Institute of Chemical Technology, Hyderabad 500007, India.
M Shaheer MalikDepartment of Chemistry, Faculty of Science, Umm Al-Qura University, Makkah 21955, Saudi Arabia.
Qazi Mohammad Sajid JamalDepartment of Health Informatics, College of Public Health and Health Informatics, Qassim University, Al Bukayriyah, Saudi Arabia.
Mufakham Ali MohammadResearch and Development Division, Saudi Chevron Phillips Company, Jubail Industrial City, Saudi Arabia.
Munirah M Al-RooqiDepartment of Chemistry, Faculty of Science, Umm Al-Qura University, Makkah 21955, Saudi Arabia.
Saeed S SammanDepartment of Chemistry, Faculty of Science, Taibah University, Madina, Saudi Arabia.
Shaikh Thoukhir BashaDepartment of Medicinal Chemistry and Pharmacology, CSIR- Indian Institute of Chemical Technology, Hyderabad 500007, India.
Abdulrahman A AlsimareeDepartment of Chemistry, College of Science and Humanities, Shaqra University, Shaqra, Saudi Arabia.
Ziad MoussaDepartment of Chemistry, College of Science, United Arab Emirates University, P.O. Box 15551, Al Ain, United Arab Emirates.
Saleh A AhmedDepartment of Chemistry, Faculty of Science, Umm Al-Qura University, Makkah 21955, Saudi Arabia.
Ahmed KamalDepartment of Medicinal Chemistry and Pharmacology, CSIR- Indian Institute of Chemical Technology, Hyderabad 500007, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and purpose: Malaria remains a formidable global healthcare challenge due to emerging drug-resistant Plasmodium spp., underscoring the urgent need for novel antimalarial scaffolds. Thiolactomycin, a FAS-II inhibitor, is a promising lead for structural optimization. This study aims to design, synthesize, and evaluate a series of thiomorpholino and piperidino conjugates bearing a thiolactone moiety as target-specific antimalarial agents. Experimental approach: A series of thiolactomycin-based conjugates was synthesized, including intermediate Findings/Results: Biological evaluation identified Conclusion and implications: Conjugate

Indexed as

AntimalarialBinding free energyMD simulationsMultitarget dockingPfFabI enzyme inhibitionThiolactomycin conjugates.

Identifiers

PMID42836196
PMCPMC13637940

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.